Bancorpsouth Decreased Johnson & Johnson (JNJ) Holding; 3 Analysts Covering ICU Medical, Inc. (ICUI)

January 12, 2018 - By marketbeat

Among 5 analysts covering ICU Medical (NASDAQ:ICUI), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. ICU Medical had 11 analyst reports since August 11, 2015 according to SRatingsIntel. Roth Capital maintained the stock with “Hold” rating in Wednesday, August 9 report. The stock has “Buy” rating by Gabelli on Friday, March 11. The rating was maintained by TH Capital on Tuesday, August 11 with “Buy”. TH Capital maintained the stock with “Buy” rating in Friday, November 6 report. The stock of ICU Medical, Inc. (NASDAQ:ICUI) earned “Buy” rating by Roth Capital on Friday, November 6. The stock has “Buy” rating by Roth Capital on Tuesday, August 11. Zacks upgraded it to “Hold” rating and $142 target in Monday, August 17 report. The rating was maintained by Piper Jaffray on Tuesday, August 11 with “Overweight”. The company was maintained on Friday, August 11 by Gabelli. See ICU Medical, Inc. (NASDAQ:ICUI) latest ratings:

17/10/2017 Broker: KeyBanc Capital Markets Rating: Sector Weight Initiates Coverage On
11/08/2017 Broker: Gabelli Rating: Buy Maintain
09/08/2017 Broker: Roth Capital Rating: Hold New Target: $172.0000 Maintain

Bancorpsouth Inc decreased Johnson & Johnson (JNJ) stake by 90.34% reported in 2017Q3 SEC filing. Bancorpsouth Inc sold 31,197 shares as Johnson & Johnson (JNJ)’s stock rose 6.85%. The Bancorpsouth Inc holds 3,336 shares with $434,000 value, down from 34,533 last quarter. Johnson & Johnson now has $391.64B valuation. The stock increased 0.68% or $0.99 during the last trading session, reaching $145.78. About 4.38 million shares traded. Johnson & Johnson (NYSE:JNJ) has risen 12.54% since January 12, 2017 and is uptrending. It has underperformed by 4.16% the S&P500.

ICU Medical, Inc. develops, manufactures, and sells medical devices used in infusion therapy, critical care, and oncology applications worldwide. The company has market cap of $4.44 billion. It offers infusion therapy products comprising a tube running from a bottle or plastic bag containing a solution to a catheter inserted in a patientÂ’s vein for use in hospitals and ambulatory clinics. It has a 155.77 P/E ratio. The companyÂ’s infusion therapy products include needlefree connector products, such as MicroClave and MicroClave Clear, Neutron, NanoClave, Clave, and SwabCap; custom infusion sets; and Tego needlefree hemodialysis connectors.

Investors sentiment decreased to 0.86 in Q3 2017. Its down 0.20, from 1.06 in 2017Q2. It dropped, as 23 investors sold ICU Medical, Inc. shares while 74 reduced holdings. 30 funds opened positions while 53 raised stakes. 15.58 million shares or 0.61% more from 15.48 million shares in 2017Q2 were reported. Ls Inv Lc holds 0.01% of its portfolio in ICU Medical, Inc. (NASDAQ:ICUI) for 576 shares. Tennessee-based Delta Asset Limited Company Tn has invested 0% in ICU Medical, Inc. (NASDAQ:ICUI). Shine Investment Advisory Svcs holds 0.01% in ICU Medical, Inc. (NASDAQ:ICUI) or 52 shares. Citadel Advsr Limited Liability Co stated it has 97,579 shares or 0.01% of all its holdings. State Common Retirement Fund has invested 0.02% in ICU Medical, Inc. (NASDAQ:ICUI). Fiera Cap Corporation invested in 238,301 shares. Personal Capital Advsr owns 0.04% invested in ICU Medical, Inc. (NASDAQ:ICUI) for 11,411 shares. Lyon Street Capital Ltd stated it has 1.34% in ICU Medical, Inc. (NASDAQ:ICUI). 133,039 were accumulated by Kennedy Cap Mgmt Inc. Eqis Capital Mngmt, a California-based fund reported 2,359 shares. Mason Street Advisors Limited Liability Corp stated it has 0.02% of its portfolio in ICU Medical, Inc. (NASDAQ:ICUI). Tiaa Cref Inv Mgmt Ltd Liability invested in 39,703 shares or 0.01% of the stock. 182,715 are held by Bank Of New York Mellon. Boston Family Office owns 4,500 shares or 0.09% of their US portfolio. Dimensional Fund Advsrs L P holds 349,725 shares or 0.03% of its portfolio.

Since August 31, 2017, it had 0 buys, and 8 sales for $27.49 million activity. 3,400 shares were sold by SWINNEY ROBERT S, worth $591,522. $420,950 worth of ICU Medical, Inc. (NASDAQ:ICUI) was sold by Jain Vivek. 1,784 ICU Medical, Inc. (NASDAQ:ICUI) shares with value of $311,248 were sold by Sanzone Virginia Ruth. $5.20 million worth of stock was sold by Lamb Scott E on Thursday, January 4. SAUCEDO JOSEPH R sold 9,000 shares worth $1.71 million.

The stock increased 0.58% or $1.3 during the last trading session, reaching $224. About 97,329 shares traded. ICU Medical, Inc. (NASDAQ:ICUI) has risen 61.84% since January 12, 2017 and is uptrending. It has outperformed by 45.14% the S&P500.

Analysts await Johnson & Johnson (NYSE:JNJ) to report earnings on January, 23. They expect $1.72 earnings per share, up 8.86% or $0.14 from last year’s $1.58 per share. JNJ’s profit will be $4.62B for 21.19 P/E if the $1.72 EPS becomes a reality. After $1.90 actual earnings per share reported by Johnson & Johnson for the previous quarter, Wall Street now forecasts -9.47% negative EPS growth.

Among 23 analysts covering Johnson & Johnson (NYSE:JNJ), 12 have Buy rating, 5 Sell and 6 Hold. Therefore 52% are positive. Johnson & Johnson had 84 analyst reports since August 7, 2015 according to SRatingsIntel. The rating was upgraded by Deutsche Bank to “Buy” on Tuesday, September 29. The firm has “Hold” rating given on Wednesday, April 6 by Societe Generale. Citigroup maintained the stock with “Buy” rating in Monday, October 23 report. The stock of Johnson & Johnson (NYSE:JNJ) has “Buy” rating given on Wednesday, October 18 by Wells Fargo. The stock of Johnson & Johnson (NYSE:JNJ) earned “Buy” rating by BMO Capital Markets on Tuesday, July 18. The company was maintained on Wednesday, October 18 by Jefferies. The firm has “Buy” rating by Argus Research given on Wednesday, April 20. As per Thursday, August 31, the company rating was maintained by UBS. As per Tuesday, September 13, the company rating was maintained by Jefferies. The rating was maintained by Stifel Nicolaus on Tuesday, July 18 with “Hold”.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts